Loading…
Major Chinese independent clinical laboratory chain providing outsourced diagnostic testing to hospitals.
Major Chinese independent clinical laboratory chain providing outsourced diagnostic testing to hospitals.
Is paid per test: hospitals send samples to its labs, or have it run their lab, and it bills the hospital or health authority, so income tracks testing volumes and local price cuts. COVID testing was a large one-time boost to volumes in 2020 to 2022, which later receded.
In one line: A Chinese LabCorp/Quest Diagnostics.
Moat: narrow (scale, installed base). National lab network and hospital relationships are costly for smaller labs to replicate.
Headquarters: Hangzhou, Zhejiang, China · Founded: 1996 · Employees: 7,462
Size Dian Diagnostics (300244.SZ) is a China Health Care company (Medical/Nursing Services) with a market value of $1.97B, the 1285th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥21.44 on 6 Nov 2026.
Performance Over six months the shares gained 10.9%, against +25.1% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 5.3% over the last twelve months (peer median +5.9%); the operating margin is 8.6% (peer median 4.7%).
Valuation It trades at 25.2× forward earnings against a peer median of 40.3× (6th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points above its cost of capital (8.7% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥9.94B | CN¥10.1B | CN¥12.2B | CN¥13.4B | CN¥20.2B |
| Revenue growth | — | -17% | -9% | -34% | — |
| Gross profit | CN¥3.26B | CN¥2.77B | CN¥3.31B | CN¥4.07B | CN¥7.40B |
| EBITDA | n/a | CN¥1.03B | CN¥1.23B | CN¥1.79B | CN¥4.55B |
| Net income | CN¥469M | CN¥44.1M | -CN¥357M | CN¥307M | CN¥1.43B |
| Free cash flow | CN¥1.73B | CN¥1.75B | CN¥847M | CN¥1.23B | CN¥776M |
| Capital expenditure | CN¥249M | CN¥285M | CN¥363M | CN¥702M | CN¥948M |
| Total debt | CN¥1.54B | CN¥2.68B | CN¥3.66B | CN¥4.29B | CN¥6.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Dian Diagnostics 300244.SZ | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% |
| Guangzhou Kingmed Diagnostics 603882.SS | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% |
| ADICON 9860.HK | $408M | +9% | +1% | 4% | 25.5× | 12.0% |
| Labcorp LH | $29.8B | +45% | +6% | 11% | 19.0× | 13.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300244.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.7% | +8.0% | 8th highest of 21 |
| 6-month return | +10.9% | +25.1% | 6th lowest of 21 |
| Distance from 52-week high | -35.6% | -13.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | -5.3% | +5.9% | 2nd lowest of 21 |
| Operating margin | 8.6% | 4.7% | 7th highest of 21 |
| Forward P/E | 25.2× | 40.3× | 6th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 2.4% | 13.4% | 4th least demanding of 16 |
| Growth delivered (Del g) | -1.1% | +8.9% | 3rd lowest of 16 |
| Hurdle (Req g minus delivered) | +3.5 pp | +7.0 pp | 7th least demanding of 16 |
| ROIC minus cost of capital | +0.3 pp | -3.3 pp | 7th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 67.5× | n/a | n/a |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 98.7× | n/a | n/a |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 58.9× | n/a | n/a |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% | +14.6% |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% | +13.2% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 12.9× | -4.5% | +2.0% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% | +10.2% |